YRHAM
RXRX icon

Yong Rong (HK) Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Yong Rong (HK) Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,174,200
Closed -$8.77M – 23
2023
Q2 		$8.77M Buy
+1,174,200
New +$8.22M 3.85% 6
2021
Q4 		– Sell
-377,000
Closed -$8.68M – 23
2021
Q3 		$8.68M Buy
+377,000
New +$10.7M 5.69% 9

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Yong Rong (HK) Asset Management's RXRX Position: Q3 2023 in Review

Yong Rong (HK) Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2023, closing a stake of 1,174,200 shares — an estimated $8.77M sold.

Yong Rong (HK) Asset Management first reported a position in RXRX in Q3 2021 and held it in 2 quarters. The position peaked at $8.77M in Q2 2023. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

  • Yong Rong (HK) Asset Management reported no remaining Recursion Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Yong Rong (HK) Asset Management sold 1,174,200 Recursion Pharmaceuticals shares in Q3 2023, an estimated $8.77M.
  • Yong Rong (HK) Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Yong Rong (HK) Asset Management's Recursion Pharmaceuticals position peaked at $8.77M in Q2 2023.
  • 192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Yong Rong (HK) Asset Management's 13F filing for Q3 2023, filed 19 Oct 2023.